CY1115841T1 - Εμβολια πεπτιδιου παραγομενα απο epha4 - Google Patents

Εμβολια πεπτιδιου παραγομενα απο epha4

Info

Publication number
CY1115841T1
CY1115841T1 CY20141101067T CY141101067T CY1115841T1 CY 1115841 T1 CY1115841 T1 CY 1115841T1 CY 20141101067 T CY20141101067 T CY 20141101067T CY 141101067 T CY141101067 T CY 141101067T CY 1115841 T1 CY1115841 T1 CY 1115841T1
Authority
CY
Cyprus
Prior art keywords
peptides
present
epea4
shape
seq
Prior art date
Application number
CY20141101067T
Other languages
English (en)
Inventor
Takuya Tsunoda
Ryuji Ohsawa
Original Assignee
Oncotherapy Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science, Inc. filed Critical Oncotherapy Science, Inc.
Publication of CY1115841T1 publication Critical patent/CY1115841T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46443—Growth factors
    • A61K39/464434—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464462—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει πεπτίδια που έχουν αλληλουχία αμινοξέος όπως εκτίθεται στη SEQ ID NO: SEQ ID NO: 19, 22, 30, 34, 344,358, 41, 44, 46, 48, 78, 376,379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117,121, 395,133,135,137, 426, 174,178,186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 ή 288, καθώς επίσης πεπτίδια που έχουν τις ανωτέρω αναφερθείσες αλληλουχίες αμινοξέος, όπου 1,.2 ή μερικά (π.χ., μέχρι 5) αμινοξέα έχουν υποκατασταθεί, απαλειφθεί ή προστεθεί, υπό την προϋπόθεση ότι τα πεπτίδια έχουν κυτταροτοξική διεγερσιμότητα Τ κυττάρου. Η παρούσα εφεύρεση επίσης παρέχει φάρμακα για θεραπεία ή αποτροπή ασθένειας που συνδυάζεται με υπερ-έκφραση των CDH3, ΕΡΗΑ4, ECT2, HIG2, INHBB, KIF20A, KNTC2, ΤΤΚ ή/και URLC10, π.χ. καρκίνων, που περιέχουν ως δραστικό συστατικό ένα ή περισσότερα από αυτά τα πεπτίδια. Τα πεπτίδια της παρούσας εφεύρεσης βρίσκουν περαιτέρω χρησιμότητα ως εμβόλια.
CY20141101067T 2007-02-21 2014-12-18 Εμβολια πεπτιδιου παραγομενα απο epha4 CY1115841T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90294907P 2007-02-21 2007-02-21
EP12151711.4A EP2465864B1 (en) 2007-02-21 2008-02-21 EphA4 derived peptide vaccines

Publications (1)

Publication Number Publication Date
CY1115841T1 true CY1115841T1 (el) 2017-01-25

Family

ID=39709837

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100994T CY1114590T1 (el) 2007-02-21 2013-11-08 Εμβολια πεπτιδιου για καρκινους που εκφραζουν ογκο-συναφη αντιγονα
CY20141101067T CY1115841T1 (el) 2007-02-21 2014-12-18 Εμβολια πεπτιδιου παραγομενα απο epha4

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20131100994T CY1114590T1 (el) 2007-02-21 2013-11-08 Εμβολια πεπτιδιου για καρκινους που εκφραζουν ογκο-συναφη αντιγονα

Country Status (28)

Country Link
EP (20) EP2570428A3 (el)
JP (6) JP5239103B2 (el)
KR (8) KR101644871B1 (el)
CN (4) CN104292299B (el)
AR (1) AR068302A1 (el)
AU (1) AU2008218463B2 (el)
BR (1) BRPI0808421B1 (el)
CA (3) CA2992074C (el)
CO (1) CO6190536A2 (el)
CY (2) CY1114590T1 (el)
DK (3) DK2465864T3 (el)
ES (6) ES2435194T3 (el)
HK (7) HK1134507A1 (el)
HR (3) HRP20131044T1 (el)
IL (10) IL200478A (el)
MX (4) MX337456B (el)
MY (2) MY173379A (el)
NZ (4) NZ579768A (el)
PH (1) PH12014501642A1 (el)
PL (3) PL2476694T3 (el)
PT (2) PT2465864E (el)
RU (1) RU2464275C2 (el)
SG (3) SG10201909675QA (el)
SI (3) SI2476694T1 (el)
TW (5) TWI610939B (el)
UA (1) UA100372C2 (el)
WO (1) WO2008102557A1 (el)
ZA (1) ZA200905881B (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019475A2 (en) 2003-08-20 2005-03-03 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
EP2192179B9 (en) 2007-08-20 2017-11-15 Oncotherapy Science, Inc. Cdh3 peptide and medicinal agent comprising the same
CA2729403A1 (en) 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI543767B (zh) * 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
RU2532105C2 (ru) * 2008-10-22 2014-10-27 Онкотерапи Сайенс, Инк. Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
TWI539160B (zh) * 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
BRPI0923402A2 (pt) * 2008-12-24 2015-08-04 Oncotherapy Science Inc Peptídeos c10rf59 e vacinas incluindo os mesmos.
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
EP3450459B1 (en) 2009-12-28 2021-05-26 OncoTherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
ES2575160T3 (es) * 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
TWI538685B (zh) * 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
UA110119C2 (xx) * 2010-12-02 2015-11-25 Пептиди tomm34 та вакцини, що їх містять
KR102144452B1 (ko) * 2011-12-14 2020-08-18 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 암 요법을 위한 병립 유전자 비활성화 생물표식과 표적들
US20150359864A1 (en) * 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
JP6255594B2 (ja) * 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン
JP6259983B2 (ja) 2012-07-10 2018-01-17 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＫＩＦ２０Ａエピトープペプチドおよびこれを含有するワクチン
EP2891663B8 (en) 2012-08-31 2018-04-04 Vasculead Inc. Psf1-derived peptide
MX362912B (es) 2012-09-11 2019-02-22 Oncotherapy Science Inc Péptidos ube2t y vacunas que incluyen los mismos.
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
AU2014288127A1 (en) * 2013-07-12 2016-02-18 Sapporo Medical University Tumor antigen peptide
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
AU2015283704A1 (en) 2014-07-01 2016-12-15 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
ES2856834T3 (es) * 2014-08-04 2021-09-28 Oncotherapy Science Inc Péptido derivado de URLC10 y vacuna que contiene el mismo
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) * 2015-06-05 2018-11-02 复旦大学附属肿瘤医院 一组用于评估肺癌预后的基因及其应用
TWI781928B (zh) * 2016-03-31 2022-11-01 美商百歐恩泰美國公司 新抗原及其使用方法
CN110214144B (zh) * 2016-11-16 2023-05-02 深圳华大生命科学研究院 多肽及其应用
HRP20220605T1 (hr) 2017-01-25 2022-07-08 Ose Immunotherapeutics Postupak za proizvodnju stabilne emulzije za isporuku peptida
CN110709508A (zh) * 2017-03-28 2020-01-17 朱正仑 治疗新生性疾病的方法
EP3666888A4 (en) * 2017-08-10 2021-09-01 Good T Cells, Inc. T-CELL ACTIVATION METHOD FOR CANCER TREATMENT
MY182816A (en) * 2018-02-15 2021-02-05 National Univ Corporation Asahikawa Medical Univ Cancer antigen peptide
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN117143206B (zh) * 2023-08-03 2024-09-03 华南农业大学 Alv-j mhc-b21限制性表位肽及其筛选方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IL103928A0 (en) * 1991-12-11 1993-04-04 American Home Prod Expression of specific immunogens using viral antigens
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
EP1464706A3 (en) * 1994-04-15 2004-11-03 Amgen Inc., HEK5, HEK7, HEK8, HEK11, EPH-like receptor protein tyrosine kinases
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
AU6632496A (en) 1995-08-03 1997-03-05 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
AU6795898A (en) * 1997-04-04 1998-10-30 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US20020102542A1 (en) * 1997-10-07 2002-08-01 Daikichi Fukushima Polypeptide, cdna encoding the polypeptide, and use of the both
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
AU1220001A (en) * 1999-10-20 2001-04-30 Zymogenetics Inc. Novel proteins and polynucleotides encoding them
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
AU2001277172A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-trans protein and related reagents and methods of use thereof
US6830885B1 (en) * 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
WO2002078524A2 (en) * 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
EP1463928A2 (en) 2001-04-18 2004-10-06 Protein Design Labs Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002347428A1 (en) * 2001-06-18 2003-01-02 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2003080640A1 (en) * 2002-03-07 2003-10-02 Ludwig Institute For Cancer Research Lymphatic and blood endothelial cell genes
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
AU2003295328A1 (en) * 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1572736A2 (en) * 2002-12-10 2005-09-14 Endocube SAS Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
WO2004058153A2 (en) * 2002-12-20 2004-07-15 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
TWI324608B (en) * 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005019475A2 (en) * 2003-08-20 2005-03-03 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
US20070253954A1 (en) * 2004-02-27 2007-11-01 Oncotherapy Science, Inc. Epha4 As Therapeutic Target Of Prc And Pdaca
KR101234281B1 (ko) * 2004-04-09 2013-02-18 가부시키가이샤 진케어켄큐쇼 염색체 안정화에 관한 유전자를 표적으로 하는 암세포 특이적 아포토시스 유도제
WO2005118626A2 (en) * 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
CN101160524A (zh) * 2005-02-24 2008-04-09 西米尼斯公司 用于生物样品分类的组合物和方法
DK2325305T3 (en) * 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines for cancers that express TTK-, URLC10- or KOC1 polypeptide
CN100348614C (zh) * 2005-06-03 2007-11-14 北京大学 一种肝癌－睾丸特异性抗原蛋白质和抗原肽
EP1930427B1 (en) * 2005-08-09 2012-04-11 Kurume University Squamous cell carcinoma antigen-derived peptide binding to hla-a24 molecule
JP5299942B2 (ja) * 2005-08-09 2013-09-25 オンコセラピー・サイエンス株式会社 ＨＬＡ−Ａ２陽性者用ｇｌｙｐｉｃａｎ−３（ＧＰＣ３）由来癌拒絶抗原ペプチド及びこれを含む医薬
US8003770B2 (en) 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
WO2007064743A2 (en) * 2005-11-30 2007-06-07 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
CN103351425B (zh) * 2006-04-10 2016-01-20 健泰科生物技术公司 散乱蛋白pdz调节剂
CN103435683B (zh) * 2006-06-16 2016-02-03 肿瘤疗法·科学股份有限公司 来自sparc的癌排斥抗原肽以及含有该肽的药物
EP1972639A3 (en) * 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) * 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP2192179B9 (en) * 2007-08-20 2017-11-15 Oncotherapy Science, Inc. Cdh3 peptide and medicinal agent comprising the same
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI543767B (zh) * 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
WO2011039289A1 (de) * 2009-09-29 2011-04-07 Protagen Ag Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung

Also Published As

Publication number Publication date
CA2678755C (en) 2016-04-26
JP2013091645A (ja) 2013-05-16
TWI494319B (zh) 2015-08-01
TWI596109B (zh) 2017-08-21
IL219042A (en) 2016-03-31
MX337417B (es) 2016-03-03
CN104292299A (zh) 2015-01-21
JP2010519176A (ja) 2010-06-03
EP2594581A3 (en) 2013-08-14
PL2465864T3 (pl) 2015-03-31
IL219041A (en) 2014-12-31
TW200844111A (en) 2008-11-16
MX337456B (es) 2016-03-03
ZA200905881B (en) 2010-05-26
CA2992074A1 (en) 2008-08-28
CA2992074C (en) 2021-01-05
HRP20131044T1 (hr) 2013-12-06
EP2476695A2 (en) 2012-07-18
EP2465866A2 (en) 2012-06-20
IL219048A (en) 2015-07-30
ES2540893T3 (es) 2015-07-14
IL219044A (en) 2014-12-31
EP2594581A2 (en) 2013-05-22
HK1134507A1 (en) 2010-04-30
EP2465867B1 (en) 2015-04-01
HK1172344A1 (en) 2013-04-19
AR068302A1 (es) 2009-11-11
CN104292299B (zh) 2017-09-29
EP2476692A2 (en) 2012-07-18
EP2567971A3 (en) 2013-06-26
TWI438207B (zh) 2014-05-21
EP2570428A2 (en) 2013-03-20
EP2476692A3 (en) 2012-12-19
HK1172041A1 (en) 2013-04-12
EP2565203A1 (en) 2013-03-06
EP2476692B1 (en) 2015-04-15
MY155029A (en) 2015-08-28
HK1172345A1 (en) 2013-04-19
JP5239104B2 (ja) 2013-07-17
TW201422637A (zh) 2014-06-16
PL2476694T3 (pl) 2015-04-30
EP2570429A3 (en) 2013-08-28
KR20140130507A (ko) 2014-11-10
EP2476693A3 (en) 2012-10-03
EP2573110A3 (en) 2013-09-04
PT2121731E (pt) 2013-10-24
KR101540000B1 (ko) 2015-07-29
PH12014501642B1 (en) 2015-12-02
HK1172042A1 (zh) 2013-04-12
IL219043A (en) 2014-12-31
RU2009135020A (ru) 2011-03-27
EP2594582A3 (en) 2013-08-14
WO2008102557A1 (en) 2008-08-28
IL219040A0 (en) 2012-05-31
ES2435194T3 (es) 2013-12-16
EP2570430A3 (en) 2013-07-10
KR20130023407A (ko) 2013-03-07
EP2121731A4 (en) 2010-04-21
KR101511140B1 (ko) 2015-04-10
EP2567971A2 (en) 2013-03-13
PL2121731T3 (pl) 2014-01-31
TWI610939B (zh) 2018-01-11
SI2121731T1 (sl) 2013-10-30
DK2465864T3 (en) 2014-11-24
CO6190536A2 (es) 2010-08-19
BRPI0808421B1 (pt) 2021-10-05
HK1172043A1 (en) 2013-04-12
IL219046A (en) 2015-02-26
EP2583976A3 (en) 2013-10-23
KR101644877B1 (ko) 2016-08-03
TW201433574A (zh) 2014-09-01
NZ602119A (en) 2014-03-28
EP2121731A1 (en) 2009-11-25
HRP20141233T1 (hr) 2015-02-27
EP2465865A3 (en) 2013-07-24
EP2476693A2 (en) 2012-07-18
EP2573109A2 (en) 2013-03-27
KR20150018895A (ko) 2015-02-24
JP5874158B2 (ja) 2016-03-02
KR20150116463A (ko) 2015-10-15
EP2476694A2 (en) 2012-07-18
EP2570430A2 (en) 2013-03-20
TW201623325A (zh) 2016-07-01
IL219041A0 (en) 2012-05-31
EP2573110A2 (en) 2013-03-27
SG10201909675QA (en) 2019-11-28
IL200478A (en) 2015-11-30
SG10201506589WA (en) 2015-09-29
KR20090121349A (ko) 2009-11-25
PT2465864E (pt) 2015-01-14
JP5614761B2 (ja) 2014-10-29
NZ602122A (en) 2014-03-28
IL219048A0 (en) 2012-05-31
EP2465864B1 (en) 2014-10-08
DK2476694T3 (en) 2014-12-08
EP2465866A3 (en) 2012-10-10
TWI615403B (zh) 2018-02-21
DK2121731T3 (da) 2013-10-21
EP2574623A3 (en) 2013-07-17
EP2570428A3 (en) 2013-07-10
IL219046A0 (en) 2012-05-31
EP2465864A3 (en) 2012-10-03
TW201538522A (zh) 2015-10-16
SG179402A1 (en) 2012-04-27
HK1172346A1 (en) 2013-04-19
EP2121731B1 (en) 2013-08-14
JP2016094459A (ja) 2016-05-26
JP5239103B2 (ja) 2013-07-17
PH12014501642A1 (en) 2015-12-02
IL219045A0 (en) 2012-05-31
EP2594582A2 (en) 2013-05-22
NZ591704A (en) 2012-09-28
ES2541863T3 (es) 2015-07-27
JP2014210804A (ja) 2014-11-13
EP2476695A3 (en) 2012-12-12
EP2573109A3 (en) 2013-06-19
AU2008218463B2 (en) 2013-01-17
KR20140121489A (ko) 2014-10-15
IL200478A0 (en) 2010-04-29
JP2010209060A (ja) 2010-09-24
EP2583976A2 (en) 2013-04-24
MX359680B (es) 2018-09-28
CA2919248A1 (en) 2008-08-28
CN103351423B (zh) 2016-09-28
MY173379A (en) 2020-01-21
ES2532708T3 (es) 2015-03-31
SI2476694T1 (sl) 2015-02-27
EP2465865B1 (en) 2016-11-02
IL219040A (en) 2014-12-31
BRPI0808421A2 (pt) 2017-08-29
HRP20150108T1 (hr) 2015-05-08
EP2476694B1 (en) 2014-11-19
IL219044A0 (en) 2012-05-31
KR20160045939A (ko) 2016-04-27
AU2008218463A1 (en) 2008-08-28
KR101644871B1 (ko) 2016-08-02
EP2570429A2 (en) 2013-03-20
MX2009009022A (es) 2010-03-03
EP2574623A2 (en) 2013-04-03
EP2465867A3 (en) 2012-10-10
NZ579768A (en) 2012-03-30
CA2678755A1 (en) 2008-08-28
CN102863514A (zh) 2013-01-09
IL219047A0 (en) 2012-05-31
KR101511134B1 (ko) 2015-04-28
ES2530777T3 (es) 2015-03-05
UA100372C2 (ru) 2012-12-25
AU2008218463A2 (en) 2009-11-26
CN102863514B (zh) 2014-12-10
KR101543623B1 (ko) 2015-08-11
JP2013116895A (ja) 2013-06-13
JP5608953B2 (ja) 2014-10-22
RU2464275C2 (ru) 2012-10-20
IL219042A0 (en) 2012-05-31
EP2476694A3 (en) 2013-04-24
EP2476693B1 (en) 2014-12-24
EP2465867A2 (en) 2012-06-20
IL219043A0 (en) 2012-05-31
CN101663315A (zh) 2010-03-03
KR20150064236A (ko) 2015-06-10
CY1114590T1 (el) 2016-10-05
EP2465865A2 (en) 2012-06-20
CN103351423A (zh) 2013-10-16
CN101663315B (zh) 2014-10-15
ES2527397T3 (es) 2015-01-23
EP2465864A2 (en) 2012-06-20
SI2465864T1 (sl) 2014-12-31

Similar Documents

Publication Publication Date Title
CY1115841T1 (el) Εμβολια πεπτιδιου παραγομενα απο epha4
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
CY1118821T1 (el) Γελες με βαση υαλουρονικο οξυ οι οποιες περιλαμβανουν αναισθητικους παραγοντες
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
BR112012013139A2 (pt) oligopeptídeos imp-3 e vacinas incluindo os mesmos
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
AR081948A2 (es) USO DE b DEFENSINAS DE MAMIFEROS PARA LA MANUFACTURA DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS DEL INTESTINO
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
AR113982A1 (es) Péptido antagonista de la actividad de la interleucina-15
TH120970A (th) เปปไทด์วัคซีนสำหรับแอนติเจนที่เกี่ยวข้องกับเนื้องอกที่เป็นมะเร็ง
TH120970B (th) เปปไทด์วัคซีนสำหรับแอนติเจนที่เกี่ยวข้องกับเนื้องอกที่เป็นมะเร็ง
ES2529713T3 (es) Péptidos anticonceptivos derivados de veneno de araña
CY1114627T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
AR107436A1 (es) Vacunas contra el cáncer